Overview

• The Grown Up Peanut Immunotherapy (GUPI) trial demonstrated that 67% of adults with severe peanut allergies could safely consume five peanuts daily after gradual exposure under medical supervision.
• This is the first clinical trial to focus exclusively on oral immunotherapy for adults, addressing a longstanding unmet need in allergy treatment.
• Participants began with microdoses of peanut flour, gradually increasing to whole peanuts over several months, with strict clinical oversight to ensure safety.
• The treatment significantly improved participants' quality of life, reducing fear of accidental exposure and enabling them to maintain desensitization through daily peanut intake.
• Researchers emphasize that larger trials are needed to confirm findings and explore the potential application of oral immunotherapy to other food allergies.